PE20191145A1 - Inhibidores de la magl - Google Patents

Inhibidores de la magl

Info

Publication number
PE20191145A1
PE20191145A1 PE2019001017A PE2019001017A PE20191145A1 PE 20191145 A1 PE20191145 A1 PE 20191145A1 PE 2019001017 A PE2019001017 A PE 2019001017A PE 2019001017 A PE2019001017 A PE 2019001017A PE 20191145 A1 PE20191145 A1 PE 20191145A1
Authority
PE
Peru
Prior art keywords
diazaspiro
hexafluoropropan
decan
decane
oxy
Prior art date
Application number
PE2019001017A
Other languages
English (en)
Inventor
Cheryl A Grice
Daniel J Buzard
Michael B Shaghafi
Original Assignee
Abide Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62145825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20191145(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abide Therapeutics Inc filed Critical Abide Therapeutics Inc
Publication of PE20191145A1 publication Critical patent/PE20191145A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Se refiere a carbamatos espirociclicos y biciclicos fusionados, un compuesto de formula I, en donde: X es -O-, -S-, -SO2-, entre otros; A es 1,8-diazaspiro[4.5]decano; 2,8-diazaspiro[4.5]decano, R1 es -(CR4R5)m-R6, entre otros; R2 puede ser halogeno, -CN, C1-6alquil, C1-6haloalquil, entre otros; R4 y R5 son cada uno independientemente seleccionados de H, F, y C1-C6 alquil; R4 y R5 junto con el carbono al que estan unidos forman un anillo C3-C6 cicloalquil; R6 es -CO2R9; R9 es H o C1-C6 alquil; m puede ser 1, 2, 3 o 4. Son compuestos preferidos: acido butanoico 4-((2-((8-(((1,1,1,3,3,3-hexafluoropropan-2-il)oxi)carbonil)-2,8-diazaspiro[4.5]decan-2-il)metil)-5-(trifluorometil)fenil)amino; acido butanoico 4-((3-((8-((1,1,1,3,3,3-hexafluoropropan-2-il)oxi)carbonil)-1,8-diazaspiro[4.5]decan)-1-il)metil)-5-(trifluorometil)fenil)amino). Dicho compuesto es modulador de la monoacilglicerol lipasa (MAGL) enzima responsable de hidrolizar endocannabinoides como el 2-AG(2-araquidonoilglicerol), y es util para el tratamiento del dolor.
PE2019001017A 2016-11-16 2017-11-15 Inhibidores de la magl PE20191145A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662423102P 2016-11-16 2016-11-16

Publications (1)

Publication Number Publication Date
PE20191145A1 true PE20191145A1 (es) 2019-09-02

Family

ID=62145825

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001017A PE20191145A1 (es) 2016-11-16 2017-11-15 Inhibidores de la magl

Country Status (27)

Country Link
US (2) US11059822B2 (es)
EP (1) EP3541820B1 (es)
JP (1) JP7042468B2 (es)
KR (1) KR20190080935A (es)
CN (1) CN110267962B (es)
AU (1) AU2017361253B2 (es)
BR (1) BR112019009880A2 (es)
CA (1) CA3043617A1 (es)
CL (1) CL2019001336A1 (es)
CO (1) CO2019004945A2 (es)
CR (1) CR20190239A (es)
DO (1) DOP2019000118A (es)
EA (1) EA038150B1 (es)
EC (1) ECSP19034535A (es)
ES (1) ES2952582T3 (es)
IL (1) IL266547B (es)
JO (1) JOP20190107A1 (es)
MA (1) MA46855A (es)
MX (1) MX2019005773A (es)
NI (1) NI201900049A (es)
PE (1) PE20191145A1 (es)
PH (1) PH12019501079A1 (es)
RU (1) RU2019115784A (es)
TN (1) TN2019000149A1 (es)
UA (1) UA125523C2 (es)
WO (1) WO2018093949A1 (es)
ZA (1) ZA201903099B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197192A1 (en) * 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
SI3541807T1 (sl) 2016-11-16 2022-01-31 H. Lundbeck A/S Kristalinična oblika zaviralca MAGL
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
BR112019009992A2 (pt) 2016-11-16 2019-08-27 Abide Therapeutics Inc formulações farmacêuticas
PL3630744T3 (pl) 2017-05-23 2023-05-15 H. Lundbeck A/S Pirazolowe inhibitory magl
MX2020002251A (es) 2017-08-29 2020-07-20 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso.
EA202090296A1 (ru) 2017-08-29 2020-08-03 Лундбекк Ла-Хойя Рисерч Сентер, Инк. Спироциклические соединения и способы их получения и применения
MX2021000549A (es) * 2018-07-19 2021-03-25 Pfizer Compuestos espiro heterociclicos como inhibidores de magl.
JP2023523219A (ja) 2020-04-21 2023-06-02 ハー・ルンドベック・アクチエゼルスカベット モノアシルグリセロールリパーゼ阻害剤の合成
TW202229255A (zh) 2020-11-13 2022-08-01 丹麥商Ｈ 朗德貝克公司 Magl抑制劑

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1003002A (en) 1910-10-10 1911-09-12 Gustave J Martel Tire-patching device.
WO2002070523A1 (en) 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
JP2009514935A (ja) * 2005-11-05 2009-04-09 アストラゼネカ・アクチエボラーグ 新規化合物
CA2665804A1 (en) 2006-08-23 2008-02-28 Astellas Pharma Inc. Urea compound or salt thereof
RU2010140613A (ru) 2008-03-05 2012-04-10 Таргасепт, Инк. (Us) Амиды диазабициклоалканов, селективные в отношении подтипа никотиновых ацетилхолиновых рецепторов
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
CA2775703C (en) 2009-09-29 2014-07-08 Polyone Corporation Polyester articles having simulated metallic or pearlescent appearance
JP5759470B2 (ja) 2009-10-23 2015-08-05 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての二置換オクタヒドロピロロ［３，４−ｃ］ピロール
EP2542083B1 (en) 2010-03-04 2015-05-06 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
EP3698782B1 (en) * 2012-01-06 2024-05-15 H. Lundbeck A/S Carbamate compounds for use in therapy
JP2014005245A (ja) * 2012-06-26 2014-01-16 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体を含有する医薬組成物
EP3590940B1 (en) 2012-09-25 2021-06-09 F. Hoffmann-La Roche AG Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases
WO2015003002A1 (en) 2013-07-03 2015-01-08 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
MD20160116A2 (ro) * 2014-04-04 2017-04-30 X-Rx Discovery, Inc Inhibitori spirociclici substituiţi ai autotaxinei
WO2015179559A2 (en) 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
CA2979537C (en) 2015-03-18 2023-08-29 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
KR20180004263A (ko) 2015-05-11 2018-01-10 어바이드 테라퓨틱스, 인크. 염증 또는 신경병성 통증의 치료 방법
BR112018000041A2 (pt) 2015-07-31 2018-09-04 Pfizer Inc. Derivados de carbamato de 1,1,1-trifluoro-3- hidroxipropan-2-ila e derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ila como inibidores de magl
CN108601769B (zh) 2015-11-20 2021-09-03 H.隆德贝克有限公司 吡唑化合物及其制备和使用方法
US10385057B2 (en) 2015-11-20 2019-08-20 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
BR112018068538B1 (pt) 2016-03-31 2023-12-12 Takeda Pharmaceutical Company Limited Composto, medicamento, e, uso de um composto
WO2017197192A1 (en) 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
JOP20190050A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
SI3541807T1 (sl) 2016-11-16 2022-01-31 H. Lundbeck A/S Kristalinična oblika zaviralca MAGL
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
BR112019009992A2 (pt) 2016-11-16 2019-08-27 Abide Therapeutics Inc formulações farmacêuticas
KR102613364B1 (ko) 2017-03-13 2023-12-14 룬드벡 라 졸라 리서치 센터 인코포레이티드 이중 magl 및 faah 저해제
JOP20190267A1 (ar) 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
PL3630744T3 (pl) 2017-05-23 2023-05-15 H. Lundbeck A/S Pirazolowe inhibitory magl
MX2020002251A (es) 2017-08-29 2020-07-20 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso.
EA202090296A1 (ru) 2017-08-29 2020-08-03 Лундбекк Ла-Хойя Рисерч Сентер, Инк. Спироциклические соединения и способы их получения и применения
TW202229255A (zh) 2020-11-13 2022-08-01 丹麥商Ｈ 朗德貝克公司 Magl抑制劑

Also Published As

Publication number Publication date
JOP20190107A1 (ar) 2019-05-09
EP3541820B1 (en) 2023-07-05
CN110267962A (zh) 2019-09-20
TN2019000149A1 (en) 2020-10-05
US20220135563A1 (en) 2022-05-05
EA201991029A1 (ru) 2019-12-30
BR112019009880A2 (pt) 2019-08-13
MX2019005773A (es) 2019-12-05
JP2020500178A (ja) 2020-01-09
US11691975B2 (en) 2023-07-04
ES2952582T3 (es) 2023-11-02
RU2019115784A3 (es) 2021-03-12
US11059822B2 (en) 2021-07-13
UA125523C2 (uk) 2022-04-13
WO2018093949A1 (en) 2018-05-24
CA3043617A1 (en) 2018-05-24
ZA201903099B (en) 2021-01-27
NI201900049A (es) 2019-10-30
EP3541820C0 (en) 2023-07-05
NZ753471A (en) 2021-01-29
JP7042468B2 (ja) 2022-03-28
DOP2019000118A (es) 2019-09-30
RU2019115784A (ru) 2020-12-17
MA46855A (fr) 2021-05-19
AU2017361253A1 (en) 2019-05-30
AU2017361253B2 (en) 2021-08-05
CN110267962B (zh) 2022-04-01
PH12019501079A1 (en) 2019-08-19
CO2019004945A2 (es) 2019-05-21
EP3541820A4 (en) 2020-06-10
CL2019001336A1 (es) 2019-10-04
KR20190080935A (ko) 2019-07-08
ECSP19034535A (es) 2019-05-31
EP3541820A1 (en) 2019-09-25
IL266547A (en) 2019-07-31
US20200291023A1 (en) 2020-09-17
EA038150B1 (ru) 2021-07-14
CR20190239A (es) 2019-06-26
IL266547B (en) 2022-06-01

Similar Documents

Publication Publication Date Title
PE20191145A1 (es) Inhibidores de la magl
PE20191144A1 (es) Inhibidores de magl
CO2021002382A2 (es) Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa
PE20161372A1 (es) Inhibidores de dihidropirrolopiridina de ror-gamma
PE20171514A1 (es) Heterociclos biciclicos como inhibidores de fgfr
PE20130155A1 (es) Derivados de ariletinilo
PE20161572A1 (es) Compuestos como moduladores de ror gamma
ES2655391T3 (es) Inhibidores isoindolinona de fosfatidilinositol 3-quinasa
PE20190801A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
AR061924A1 (es) Proceso para elaborar 2- amino -5 - halobenzamidas 3- sustituidas
AR080785A1 (es) Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros.
PE20171099A1 (es) Derivados de 5-[(piperazin-1-il)-3-oxo-propil]-imidazolidin-2,4-diona como inhibidores de adamts para el tratamiento de osteoartritis
PE20170267A1 (es) Compuestos heterociclicos y su uso como inhibidores gama-t del receptor huerfano relacionado con retinoide (ror)
PE20152032A1 (es) Compuestos de 3,4-dihidroisoquinolin-2(1h)-il
PE20181853A1 (es) 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4h-pirazolo[4,3-c]piridin-4-onas como inhibidores de pde1
AR071531A1 (es) Compuesto cristalino heteromonociclico
PE20191156A1 (es) Nuevos derivados de isoxazolil eter como pam de gabaa alfa5
PE20190339A1 (es) 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1
MA53920A (fr) Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38
AR084589A1 (es) Compuestos de amidina y su uso para el control de enfermedades de plantas
PE20160240A1 (es) Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PE20150021A1 (es) 5-amino[1,4]tiazinas como inhibidores de bace1
AR075530A1 (es) Nuevas orto-aminoamidas para el tratamiento del cancer
PE20190204A1 (es) [8-(fenilsulfonil)-3,8-diazabiciclo[3.2.1]oct-3-il](1h-1,2,3-triazol-4-il)metanonas
PE20170251A1 (es) Novedosas pirimidinas 2,5-sustituidas